Showing 3271-3280 of 5246 results for "".
- Benzac Skin Refining Mask and Benzac Acne Eliminating Cleanser from Galderma Now Available Nationwidehttps://practicaldermatology.com/news/benzac-skin-refining-mask-and-benzac-acne-eliminating-cleanser-from-galderma-now-available-nationwide/2458893/
- Cynosure's SculpSure Receives Expanded FDA Clearance for Lipolysis of the Abdomenhttps://practicaldermatology.com/news/cynosures-sculpsure-receives-expanded-fda-clearance-for-lipolysis-of-the-abdomen/2458914/Cynosure, Inc. has received 510(k) clearance from the FDA to market SculpSure™ for non-invasive lipolysis of the abdomen. In May, the FDA cleared SculpSure for non-invasive lipolysis of the flanks. SculpSure is a safe, clinically proven treatment designed to reduce fat non-invasivel
- POWER Study Suggests EpiDuo plus Doxycycline May be an Alternative to Isotretinoinhttps://practicaldermatology.com/news/power-study-suggests-epiduo-plus-doxycycline-may-be-an-alternative-to-isotretinoin/2459000/Doxycycline 200 mg plus adapalene 0.1%/benzoyl peroxide 2.5% gel (D+A/BPO) is an alternative to isotretinoin in patients intolerant to, or unable or unwilling to take, oral isotretinoin, and is an option for treatment of severe nodular acne, according to a new study. Findings suggest that th
- Kythera Acquires Rights to Experimental Hair Loss Treatmenthttps://practicaldermatology.com/news/kythera-acquires-rights-to-experimental-hair-loss-treatment/2459008/Kythera Biopharmaceuticals has struck two separate license agreements with Actelion Pharmaceuticals and the University of Pennsylvania for a potential novel treatment of hair loss. In the agreement with Actelion, Kythera gained licensing of the worldwide rights to setipiprant, a clinical-stage se
- Lumenis Expands Product Line with a New ResurFX Systemhttps://practicaldermatology.com/news/lumenis-expands-product-line-with-a-new-resurfx-system/2459013/Lumenis Ltd. launched its new ResurFX™ laser system for fractional non-ablative skin resurfacting treatments. This new ResurFX system is a stand-alone desktop solution, which builds upon the successful launch of ResurFX module for the M22™ multi-application platform. The system d
- Vivacare Launches "Find a Dermatologist" Directory with "Expert Opinion" Functionhttps://practicaldermatology.com/news/vivacare-launches-find-a-dermatologist-directory-with-expert-opinion-function/2459044/Vivacare has launched its new <a href="http://www.findadermatologist.com" target="_blank">Find a Dermatolog
- Syneron Candela Expands Capabilities of UltraShape Platform, Receives FDA Clearance for the New U-Sculpt Transducer and Enhanced Ultrasound Powerhttps://practicaldermatology.com/news/20141117-syneron_candela_expands_capabilities_of_ultrashape_platform_receives_fda_clearance_for_the_new_u-sculpt_transducer_and_enhanced_ultrasound_power/2459064/The FDA cleared Syneron Medical Ltd.'s U-Sculpt transducer for the UltraShape non-invasive fat destruction platform. The FDA also cleared the V3.1 platform for a 25 percent increase in Ultrasound power in the new U-sculpt transducer and the previously cleared larger VDF transducer. This 25 percen
- Novartis data at EADV show consistent efficacy of AIN457 (secukinumab) in clearing skin of psoriasis patientshttps://practicaldermatology.com/news/20141013-novartis_data_at_eadv_show_consistent_efficacy_of_ain457_secukinumab_in_clearing_skin_of_psoriasis_patients/2459087/Novartis announced that new analyses of AIN457 (secukinumab) Phase III studies showed that treatment with secukinumab 300 mg resulted in higher rates of clear to almost clear skin at Week 12 versus placebo, regardless of patients' psoriasis disease severity (p<0.0001)[1].
- Trevi Therapeutics Announces the Issuance of Two Patents for Oral Sustained Release Formulation of Nalbuphine ERhttps://practicaldermatology.com/news/20140815-trevi_therapeutics_announces_the_issuance_of_two_patents_for_oral_sustained_release_formulation_of_nalbuphine_er/2459144/Trevi Therapeutics, Inc. received two issued U.S. patents with claims protecting the oral sustained release formulation of nalbuphine. The patent numbers are 8,771,732 and 8,765,175. The Company believes that both of these patents will be Orange Book-li
- Valeant Commences Exchange Offer For Allerganhttps://practicaldermatology.com/news/20140618-valeant_commences_exchange_offer_for_allergan/2459201/